Autoimmune disease

University of Birmingham
#Autoimmune disease #Collaboration #Funding #Immune system #Osaka University #University of Birmingham #University of Oxford

Birmingham Uni and Nobel winner secure inflammation funding

Scientists and clinician-scientists at the University of Birmingham will lead a major research programme to transform the treatment of autoimmune diseases by halting chronic inflammation at its source.  Backed by a £3.83 ($5.1) million Wellcome Discovery Award, Birmingham researchers will join 2025 Nobel Prize winner Professor Shimon… Read More

#News

CAR-T cell therapy
#Autoimmune disease #CAR-T #Cell therapy #Immunotherapy #Ulcerative colitis (UC)

First use of CAR-T therapy to treat ulcerative colitis

A team of physicians at the German Center for Immunotherapy at Erlangen University Hospital has succeeded for the first time worldwide in treating a 21-year-old female patient with therapy-resistant, severe chronic inflammatory bowel disease (ulcerative colitis) using cell therapy with CD19 CAR-T cells.  The 21-year-old patient had… Read More

#Editor's Choice #News

#Autoimmune disease #Diabetes #Mergers and acquisitions #Metabolic diseases

Barinthus Bio and Clywedog Therapeutics announce merger

Immunology and inflammation company Barinthus Biotherapeutics and private company Clywedog Therapeutics will merge to target metabolic and autoimmune diseases, the companies have announced.  The combined company, named Clywedog Therapeutics, will now advance a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases. The portfolio includes three differentiated, clinical stage… Read More

#Business & Investment #News

FDA
#Autoimmune disease #Clinical trials #Drug approvals #FDA

FDA approves first BTK inhibitor for immune thrombocytopenia 

The US Food and Drug Administration (FDA) has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.   The approval was based on the pivotal LUNA 3 Phase III study, in which Wayrilz met the… Read More

#News

Immunotherapy
#Autoimmune disease #Immunic Therapeutics #Immunology #MS #Neurodegenerative disorders #Neurology

Moving beyond managing autoimmune diseases to progression

What if we’re finally moving beyond managing autoimmune diseases and toward slowing their progression? That’s the promise behind Immunic Therapeutics' recent long-term data on vidofludimus calcium (IMU‑838. Dr Daniel Vitt, CEO of Immunic, discusses these results and insights with DDW’s Megan Thomas. MT: Can you unpack what the sustained neuroprotective… Read More

#Exclusive Content

Monoclonal antibody
#AbbVie #Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Monoclonal antibodies #Oncology

AbbVie licenses trispecific antibody in billion-dollar contract

IGI Therapeutics, a wholly owned subsidiary of Ichnos Glenmark Innovation, and AbbVie have announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, for oncology and autoimmune diseases.  “Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by… Read More

#Business & Investment #News

Research scientists in laboratory
#Arialys Therapeutics #Autoimmune disease #Neuropsychiatric disorders #Neuroscience #Preclinical investigations #Therapeutic Antibodies

Study supports monovalent antibody in neuropsychiatric disease

New preclinical data have demonstrated that Arialys Therapeutics’ lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioural symptoms in a non-human primate model.   The company says the findings support the continued clinical development… Read More

#Editor's Choice #News

Robot holds up a pill
#Artificial intelligence (AI) #Autoimmune disease #Charles River #Lupus #Valo Health

AI identifies new product candidate for lupus

Charles River Laboratories and Valo Health have announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications.   The discovery was the first using Logica, an artificial intelligence (AI)-powered drug development solution that translates biological insights into optimised… Read More

#News

#Antibodies #Autoimmune disease #Collaboration #FcR Therapeutics #Grifols #Nanobodies

Partners to target autoimmune Fc receptors using nanobodies

Grifols and biotechnology startup, FcR Therapeutics, have agreed to collaborate on recombinant nanobodies to treat autoimmune diseases.  The nanobodies, which are small highly specialised antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of immune cells that… Read More

#Business & Investment #News

CAR-T therapy
#Allogene Therapeutics #Autoimmune disease #CAR-T #Cell therapy #FDA #Phase I trial

Allogeneic CAR-T therapy gets go-ahead for rheumatology trial

Allogene Therapeutics has been given the green light from the US Food and Drug Administration (FDA) for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR-T product.  The Phase I RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including… Read More

#Cancer Research #News #Regulatory

#Autoimmune disease #CAR-T #Cell and gene therapy #Cell therapy

Expanding access to cell therapies for autoimmune conditions

DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in the past decade has led to meaningful clinical responses across both… Read More

#Exclusive Content

#Autoimmune disease #Clinical research #Sjögren’s disease #T cell

Researchers find existing drug could treat Sjögren’s disease

Researchers are closer to understanding what drives the autoimmune disorder Sjögren’s disease, thanks to new discoveries about the role of calcium signalling, regulatory T cells, and interferon. The study, led by scientists at NYU College of Dentistry and NYU Grossman School of Medicine, was published in Science Translational Medicine. Read More

#News

Person using a calculator
#Autoimmune disease #Financing #Immunomodulators #Nuvig Therapeutics #Phase II trial

Immunomodulatory therapeutics company raises $161m

Nuvig Therapeutics has closed a $161 million Series B financing and announced plans to progress to Phase II development with its immunomodulator for inflammatory autoimmune diseases.  The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners.  There was also participation from… Read More

#Business & Investment #News

Human kidneys
#Autoimmune disease #Everest Medicines #Kidney disease #Phase I trial

Positive results for BTK inhibitor for primary membranous nephropathy

Everest Medicines has revealed positive results in the ongoing Phase Ib/IIa clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011).  In an analysis of the data, results from the trial showed that for patients in the low-dose cohort who have… Read More

#News

#Antibiotics #Autoimmune disease #Genetics / genomics #Oncology #Painkillers #T cell engagers

New DDW Highlights podcast: 25 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s most exciting news stories all represent innovative solutions to the… Read More

#News

#Antibiotics #Autoimmune disease #Genetics / genomics #Oncology #Painkillers #T cell engagers

This week in drug discovery (18-22 November) 

News round-up for 18-22 November by DDW Senior Digital Content Editor Diana Spencer. This week’s most exciting news stories all represent innovative solutions to the treatment of disease, proving that ‘thinking outside the box’ can by the key to success in drug discovery. The top stories:… Read More

#News